Tag: Vici Venous Stent

Long-term data revealed for VICI Venous Stent System

Michael Lichtenberg (Karolinen Hospital, Arnsberg, Germany) details three-year data from the Arnsberg venous registry on the VICI Venous Stent System (Boston Scientific). This video forms...
Michael Lichtenberg

Three-year data add to growing body of clinical evidence in support...

This advertorial is sponsored by Boston Scientific. The VICI Venous Stent System (Boston Scientific) is associated with excellent primary patency rates, with concomitant symptomatic improvement...

Three-year data add to growing body of clinical evidence in support...

The VICI Venous Stent System (Boston Scientific) is associated with excellent primary patency rates, with concomitant symptomatic improvement in Clinical-Etiological-Anatomical-Pathophysiological (CEAP) classification, directly after...

Boston Scientific receives US FDA approval for the Vici Venous Stent...

Boston Scientific has announced hat the US Food and Drug Administration (FDA) has approved the Vici venous stent system for the treatment of iliofemoral...

VIRTUS subanalysis identifies correlates to improved patient outcomes after venous stenting

 Mahmood Razavi (Orange, USA) reported new data from a subanalysis of the VIRTUS trial, which set out to investigate the safety and efficacy of...

VIRTUS 12-month outcomes presented at LINC: Vici stent meets primary endpoints

New 12-month data from the VIRTUS trial demonstrates that patients who were treated with the Vici Venous Stent system (Boston Scientific) for iliac and femoral...

Boston Scientific announces agreement to acquire Veniti

Boston Scientific has signed an agreement to acquire Veniti, a privately-held company in Fremont, USA which developed and commercialised the Vici venous stent system for...
Thorpe images

Venography and IVUS for the diagnosis and treatment of iliofemoral venous...

The results of the VIRTUS feasibility study—analysing the performance of the Vici venous stent system (Veniti) in achieving patency of venous lesions up to...

IVUS may be a more accurate method than venography for assessing...

Fresh data from the VIRTUS feasibility study presented at the Vascular Interventional Advances (VIVA) annual conference 2016 (18–22 September, Las Vegas, USA) suggest that...

Veniti closes on US$25m from Boston Scientific

Veniti has closed on US$25m in Series D equity financing from Boston Scientific Corporation. The funds will allow Veniti to complete the VIRTUS trial...